vs
卡地纳健康（CAH）与Meta Platforms（META）财务数据对比。点击上方公司名可切换其他公司
卡地纳健康的季度营收约是Meta Platforms的1.1倍（$65.6B vs $59.9B），Meta Platforms净利率更高（38.0% vs 0.7%，领先37.3%），Meta Platforms同比增速更快（23.8% vs 19.6%），过去两年Meta Platforms的营收复合增速更高（28.2% vs 6.9%）
卡地纳健康是美国跨国医疗服务企业，位列美国企业营收榜第15位，总部位于俄亥俄州都柏林。公司主营药品及医疗产品分销业务，服务覆盖超10万个网点，同时生产手套、手术服、流体管理产品等医疗及外科用品。
Meta Platforms是总部位于美国加利福尼亚州门洛帕克的跨国科技巨头，属于全球头部科技企业阵营。旗下运营Facebook、Instagram、WhatsApp、Messenger、Threads等多款知名社交媒体及通讯服务，同时开展自有及第三方站点广告业务，2023年广告收入占其总营收的97.8%。
CAH vs META — 直观对比
营收规模更大
CAH
是对方的1.1倍
$59.9B
营收增速更快
META
高出4.2%
19.6%
净利率更高
META
高出37.3%
0.7%
两年增速更快
META
近两年复合增速
6.9%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $65.6B | $59.9B |
| 净利润 | $467.0M | $22.8B |
| 毛利率 | 3.7% | 81.8% |
| 营业利润率 | 1.1% | 41.3% |
| 净利率 | 0.7% | 38.0% |
| 营收同比 | 19.6% | 23.8% |
| 净利润同比 | -7.7% | 9.3% |
| 每股收益（稀释后） | — | $8.87 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CAHMETA
| Q4 25 | $65.6B | $59.9B | ||
| Q3 25 | — | $51.2B | ||
| Q2 25 | $60.2B | $47.5B | ||
| Q1 25 | $54.9B | $42.3B | ||
| Q4 24 | $55.3B | $48.4B | ||
| Q3 24 | $52.3B | $40.6B | ||
| Q2 24 | $59.7B | $39.1B | ||
| Q1 24 | $54.9B | $36.5B |
净利润CAHMETA
| Q4 25 | $467.0M | $22.8B | ||
| Q3 25 | — | $2.7B | ||
| Q2 25 | $239.0M | $18.3B | ||
| Q1 25 | $506.0M | $16.6B | ||
| Q4 24 | $400.0M | $20.8B | ||
| Q3 24 | $416.0M | $15.7B | ||
| Q2 24 | $236.0M | $13.5B | ||
| Q1 24 | $258.0M | $12.4B |
毛利率CAHMETA
| Q4 25 | 3.7% | 81.8% | ||
| Q3 25 | — | 82.0% | ||
| Q2 25 | 3.7% | 82.1% | ||
| Q1 25 | 3.9% | 82.1% | ||
| Q4 24 | 3.5% | 81.7% | ||
| Q3 24 | 3.6% | 81.8% | ||
| Q2 24 | 3.1% | 81.3% | ||
| Q1 24 | 3.5% | 81.8% |
营业利润率CAHMETA
| Q4 25 | 1.1% | 41.3% | ||
| Q3 25 | — | 40.1% | ||
| Q2 25 | 0.7% | 43.0% | ||
| Q1 25 | 1.3% | 41.5% | ||
| Q4 24 | 1.0% | 48.3% | ||
| Q3 24 | 1.1% | 42.7% | ||
| Q2 24 | 0.7% | 38.0% | ||
| Q1 24 | 0.7% | 37.9% |
净利率CAHMETA
| Q4 25 | 0.7% | 38.0% | ||
| Q3 25 | — | 5.3% | ||
| Q2 25 | 0.4% | 38.6% | ||
| Q1 25 | 0.9% | 39.3% | ||
| Q4 24 | 0.7% | 43.1% | ||
| Q3 24 | 0.8% | 38.7% | ||
| Q2 24 | 0.4% | 34.5% | ||
| Q1 24 | 0.5% | 33.9% |
每股收益（稀释后）CAHMETA
| Q4 25 | — | $8.87 | ||
| Q3 25 | — | $1.05 | ||
| Q2 25 | — | $7.14 | ||
| Q1 25 | — | $6.43 | ||
| Q4 24 | — | $7.96 | ||
| Q3 24 | $1.70 | $6.03 | ||
| Q2 24 | $0.86 | $5.16 | ||
| Q1 24 | $1.07 | $4.71 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.8B | $81.6B |
| 总债务越低越好 | $8.3B | $58.7B |
| 股东权益账面价值 | $-2.9B | $217.2B |
| 总资产 | $58.1B | $366.0B |
| 负债/权益比越低杠杆越低 | — | 0.27× |
8季度趋势，按日历期对齐
现金及短期投资CAHMETA
| Q4 25 | $2.8B | $81.6B | ||
| Q3 25 | — | $44.4B | ||
| Q2 25 | $3.9B | $47.1B | ||
| Q1 25 | $3.3B | $70.2B | ||
| Q4 24 | $3.8B | $77.8B | ||
| Q3 24 | $2.9B | $70.9B | ||
| Q2 24 | $5.3B | $58.1B | ||
| Q1 24 | $3.7B | $58.1B |
总债务CAHMETA
| Q4 25 | $8.3B | $58.7B | ||
| Q3 25 | — | — | ||
| Q2 25 | $8.0B | — | ||
| Q1 25 | $7.1B | — | ||
| Q4 24 | $7.1B | $28.8B | ||
| Q3 24 | $4.2B | $28.8B | ||
| Q2 24 | $4.7B | — | ||
| Q1 24 | $4.7B | — |
股东权益CAHMETA
| Q4 25 | $-2.9B | $217.2B | ||
| Q3 25 | — | $194.1B | ||
| Q2 25 | $-2.8B | $195.1B | ||
| Q1 25 | $-2.9B | $185.0B | ||
| Q4 24 | $-3.0B | $182.6B | ||
| Q3 24 | $-3.3B | $164.5B | ||
| Q2 24 | $-3.2B | $156.8B | ||
| Q1 24 | $-3.3B | $149.5B |
总资产CAHMETA
| Q4 25 | $58.1B | $366.0B | ||
| Q3 25 | — | $303.8B | ||
| Q2 25 | $53.1B | $294.7B | ||
| Q1 25 | $49.9B | $280.2B | ||
| Q4 24 | $47.0B | $276.1B | ||
| Q3 24 | $43.1B | $256.4B | ||
| Q2 24 | $45.1B | $230.2B | ||
| Q1 24 | $45.9B | $222.8B |
负债/权益比CAHMETA
| Q4 25 | — | 0.27× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.16× | ||
| Q3 24 | — | 0.18× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $36.2B |
| 自由现金流经营现金流 - 资本支出 | — | $14.8B |
| 自由现金流率自由现金流/营收 | — | 24.8% |
| 资本支出强度资本支出/营收 | — | 35.7% |
| 现金转化率经营现金流/净利润 | — | 1.59× |
| 过去12个月自由现金流最近4个季度 | — | $46.1B |
8季度趋势，按日历期对齐
经营现金流CAHMETA
| Q4 25 | — | $36.2B | ||
| Q3 25 | — | $30.0B | ||
| Q2 25 | $1.5B | $25.6B | ||
| Q1 25 | $2.9B | $24.0B | ||
| Q4 24 | $-400.0M | $28.0B | ||
| Q3 24 | $-1.6B | $24.7B | ||
| Q2 24 | $2.1B | $19.4B | ||
| Q1 24 | $-49.0M | $19.2B |
自由现金流CAHMETA
| Q4 25 | — | $14.8B | ||
| Q3 25 | — | $11.2B | ||
| Q2 25 | $1.3B | $9.0B | ||
| Q1 25 | $2.8B | $11.1B | ||
| Q4 24 | $-499.0M | $13.6B | ||
| Q3 24 | $-1.7B | $16.5B | ||
| Q2 24 | $1.9B | $11.2B | ||
| Q1 24 | $-161.0M | $12.8B |
自由现金流率CAHMETA
| Q4 25 | — | 24.8% | ||
| Q3 25 | — | 21.8% | ||
| Q2 25 | 2.2% | 19.0% | ||
| Q1 25 | 5.1% | 26.2% | ||
| Q4 24 | -0.9% | 28.0% | ||
| Q3 24 | -3.3% | 40.6% | ||
| Q2 24 | 3.2% | 28.7% | ||
| Q1 24 | -0.3% | 35.2% |
资本支出强度CAHMETA
| Q4 25 | — | 35.7% | ||
| Q3 25 | — | 36.7% | ||
| Q2 25 | 0.4% | 34.8% | ||
| Q1 25 | 0.2% | 30.6% | ||
| Q4 24 | 0.2% | 29.8% | ||
| Q3 24 | 0.2% | 20.3% | ||
| Q2 24 | 0.3% | 20.9% | ||
| Q1 24 | 0.2% | 17.6% |
现金转化率CAHMETA
| Q4 25 | — | 1.59× | ||
| Q3 25 | — | 11.07× | ||
| Q2 25 | 6.39× | 1.39× | ||
| Q1 25 | 5.76× | 1.44× | ||
| Q4 24 | -1.00× | 1.34× | ||
| Q3 24 | -3.96× | 1.58× | ||
| Q2 24 | 8.80× | 1.44× | ||
| Q1 24 | -0.19× | 1.56× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CAH
| Pharmaceutical And Specialty Solutions | $60.7B | 92% |
| GMPD | $3.3B | 5% |
| At Home Solutions | $1.2B | 2% |
| Nuclear Precision Health Solutions | $440.0M | 1% |
| Opti Freight Logistics | $99.0M | 0% |
META
| Advertising | $58.1B | 97% |
| Reality Labs | $955.0M | 2% |
| Service Other | $801.0M | 1% |
